Get the Stockscreener App
0.632
4.24%
-0.028
Biofrontera Inc stock is traded at $0.632, with a volume of 36,649.
It is down -4.24% in the last 24 hours and down -2.72% over the past month.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
See More
Previous Close:
$0.66
Open:
$0.66
24h Volume:
36,649
Relative Volume:
0.24
Market Cap:
$5.78M
Revenue:
$34.07M
Net Income/Loss:
$-20.13M
P/E Ratio:
-0.0489
EPS:
-12.92
Net Cash Flow:
$-24.90M
1W Performance:
+3.37%
1M Performance:
-2.72%
6M Performance:
-36.43%
1Y Performance:
-38.64%
1-Day Range:
$0.6201
$0.66
1-Week Range:
$0.5881
$0.699
52-Week Range:
$0.536
$2.22
Biofrontera Inc Stock (BFRI) Company Profile
Name
Biofrontera Inc
Sector
Phone
781-245-1325
Address
120 PRESIDENTIAL WAY,, WOBURN
Compare BFRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.632 | 5.78M | 34.07M | -20.13M | -24.90M | -12.92 |
|
RGC
Regencell Bioscience Holdings Ltd
|
78.00 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
161.67 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.50 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.89 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.89 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Biofrontera Inc Stock (BFRI) Latest News
Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Increases By 74.8% - Defense World
Biofrontera Inc. (BFRI) Engages in Strategic Talks with Biofront - GuruFocus
Biofrontera Inc. Confirms Talks on Merger, Licensing Changes with Biofrontera AG - marketscreener.com
Biofrontera Inc. Negotiates Cooperation Changes with Biofrontera AG - TipRanks
Biofrontera in talks with AG parent for possible merger or deal terms - Investing.com India
Biofrontera Inc. Confirms Negotiations for Potential Combination with Biofrontera AG - Nasdaq
Biofrontera in talks with AG parent for possible merger or deal terms By Investing.com - Investing.com South Africa
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG - GlobeNewswire
National Crime Prevention Council Urges McDonald's to End Snapchat Partnership Over Child Safety Concerns - The Manila Times
Biofrontera Inc Explores Merger with Parent Company, Major US License Agreement Changes on Table - Stock Titan
Biofrontera AG Explores Strategic Changes with Biofrontera Inc. - TipRanks
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update - mx.advfn.com
Actinic Keratosis Treatment Market SWOT Analysis by Leading Expert: Almirall, Biofrontera, Nestle - newstrail.com
Biofrontera secures patent for Ameluz formulation until 2043 By Investing.com - Investing.com South Africa
biofrontera inc. revises proxy statement disclosure By Investing.com - Investing.com South Africa
biofrontera inc. revises proxy statement disclosure - Investing.com
Biofrontera Updates Proxy Statement for 2025 Meeting - TipRanks
Biofrontera Glycol-Free Skin Gel Added to FDA 'Orange Book;' Shares Rise - marketscreener.com
Biofrontera Inc. (BFRI) Propylene Glycol-Free Patent Gains FDA R - GuruFocus
Biofrontera Inc. (BFRI) Propylene Glycol-Free Patent Gains FDA Recognition | BFRI Stock News - GuruFocus
Biofrontera secures patent for Ameluz formulation until 2043 - Investing.com
Biofrontera announces inclusion of patent in FDA Orange Book - TipRanks
Biofrontera Inc. Announces Patent for Propylene Glycol-Free - GlobeNewswire
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book - Yahoo Finance
Biofrontera stock hits 52-week low at $0.58 amid market challenges By Investing.com - Investing.com South Africa
Biofrontera stock hits 52-week low at $0.58 amid market challenges - Investing.com India
Biofrontera AG Faces Financial Uncertainty Amid Biofrontera Inc. Payment Issues - TipRanks
Biofrontera Receives Nasdaq Non-Compliance Notice - TipRanks
Roth Capital Decreases Earnings Estimates for Biofrontera - Defense World
Q2 Earnings Forecast for Biofrontera Issued By Roth Capital - Defense World
Biofrontera Inc. (NASDAQ:BFRI) Q1 2025 Earnings Call Transcript - Insider Monkey
Biofrontera (NASDAQ:BFRI) Price Target Lowered to $2.75 at Benchmark - Defense World
Biofrontera, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Benchmark cuts Biofrontera stock target to $2.75, keeps Buy rating By Investing.com - Investing.com Nigeria
Photodynamic Therapy Market Trends Report 2025-2033, Competitive Analysis of Gladerma, Sun Pharma, Biofrontera, Lumibird, Bausch Health, Soligenix, Modulight, and Theralase TechnologiesResearchAndMarkets.com - FinancialContent
Biofrontera (BFRI) Sees Price Target Reduction by Benchmark | BF - GuruFocus
Benchmark cuts Biofrontera stock target to $2.75, keeps Buy rating - Investing.com Australia
Biofrontera (BFRI) Target Price Trimmed After Lower Revenue Perf - GuruFocus
Biofrontera Inc. price target lowered to $2.75 from $7 at Benchmark - TipRanks
Biofrontera signals 2025 record revenue ambitions with new Ameluz patent and cost controls - MSN
Biofrontera Inc. (BFRI) Reports 9% Revenue Growth in Q1 2025 - GuruFocus
Earnings call transcript: Biofrontera Q1 2025 sees revenue rise, stock dips - Investing.com Nigeria
Earnings call transcript: Biofrontera Q1 2025 sees revenue rise, stock dips By Investing.com - Investing.com South Africa
Transcript : Biofrontera Inc., Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com
BFRI Increases Q1 Revenue and Expands Market Presence | BFRI Sto - GuruFocus
Biofrontera Inc Stock (BFRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):